The registration process for Claritas’ software products is underway. Credit: Gorodenkoff / Shutterstock.

Claritas NucMed Technologies has cleared regulatory requirements for establishing its subsidiary, Claritas NucMed Tech Brazil, to advance the commercialisation of its nuclear medicine software solutions.

Claritas’ software device is designed to meet the challenges of the nuclear medicine sector in Brazil, including environmental impact, high costs, and access issues.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Through its approved distributor New Vida Medicamentos e Productos, the subsidiary is set to deploy and collaborate on positron emission tomography (PET) and single photon emission computed tomography (SPECT) software suites with medical institutions in the country.

The registration process for Claritas NucMed’s software products is underway with ANVISA, Brazil’s medical device regulator.

These products are designed for accelerated and reduced isotope scans and automated lesion detection.

Claritas NucMed Tech Brazil managing director Dr Fernando Salis said: “In terms of the number of PET-CT scans alone, the current estimated number stands at about 20,000 per month, up from only 1,800 per month ten years ago.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Despite growth rates that are estimated at 7% per year, there are shortages with demand outstripping supply due to the long scanning time and the challenges of high cost, short life and transportation issues of the isotopes.

“This is the perfect time for the introduction of solutions from Claritas NucMed, which could help to improve efficiencies, reduce costs and provide patient benefits.”

In May 2024, Claritas HealthTech announced the completion of iPETcertum, a new software device designed to automate the detection, delineation, and quantification of isotope uptake in PET scans.

This device already obtained US Food and Drug Administration (FDA) 510k clearance and is commercially available.